Cytomegalovirus and immunotherapy: Opportunistic pathogen, novel target for cancer and a promising vaccine vector

Immunotherapy

Volumn 8, Issue 2, 2016, Pages 211-221

  Quinn, Michael ^a   Erkes, Dan A ^a   Snyder, Christopher M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

adoptive immunotherapy; cytomegalovirus; immunotherapy; memory T cells; vaccination

Indexed keywords

CYTOMEGALOVIRUS VACCINE; VIRUS VECTOR; CANCER VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSURVEILLANCE; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; THERAPEUTIC USE;

CANCER VACCINES; CYTOMEGALOVIRUS; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84956905789     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.110     Document Type: Review

References (98)

1. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J. Mol. Biol. 247(3), 443-458 (1995).
2. Mocarski ES, Shenk T, Pass RF. Fields Virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, USA (2007).
3. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22(1), 76-98 (2009).
4. Hansen SG, Vieville C, Whizin N et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15(3), 293-299 (2009).
5. Hansen SG, Ford JC, Lewis MS et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348), 523-527 (2011).
6. Hansen SG, Sacha JB, Hughes CM et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340(6135), 1237874 (2013).
7. Hansen SG, Piatak MJ, Ventura AB et al. Immune clearance of highly pathogenic SIV infection. Nature 502(7469), 100-104 (2013).
8. Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc. Soc. Exp. Biol. Med. 92(2), 424-430 (1956).
9. Krmpotic A, Bubic I, Polic B, Lucin P, Jonjic S. Pathogenesis of murine cytomegalovirus infection. Microbes Infect. 5(13), 1263-1277 (2003).
10. Reddehase MJ, Simon CO, Seckert CK, Lemmermann N, Grzimek NK. Murine model of cytomegalovirus latency and reactivation. Curr. Top. Microbiol. Immunol. 325, 315-331 (2008).
11. Schleiss MR. Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next. Future Virol. 8(12), 1161-1182 (2013).
12. Jarvis MA, Nelson JA. Human cytomegalovirus persistence and latency in endothelial cells and macrophages. Curr. Opin. Microbiol. 5(4), 403-407 (2002).
13. Koffron AJ, Hummel M, Patterson BK et al. Cellular localization of latent murine cytomegalovirus. J. Virol. 72(1), 95-103 (1998).
14. Pollock JL, Presti RM, Paetzold S, Virgin HWT. Latent murine cytomegalovirus infection in macrophages. Virology 227(1), 168-179 (1997).
15. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78(5), 1373-1380 (1991).
16. Polic B, Hengel H, Krmpotic A et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188(6), 1047-1054 (1998).
17. Reddehase MJ, Weiland F, Munch K et al. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J. Virol. 55(2), 264-273 (1985).
18. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257(5067), 238-241 (1992).
19. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83(7), 1971-1979 (1994).
20. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333(16), 1038-1044 (1995).
21. Karrer U, Sierro S, Wagner M et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J. Immunol. 170(4), 2022-2029 (2003).
22. Komatsu H, Sierro S, V Cuero A, Klenerman P. Population analysis of antiviral T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol. 134(1), 9-12 (2003).
23. Appay V, Dunbar PR, Callan M et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8(4), 379-385 (2002).
24. Snyder CM, Cho KS, Bonnett EL et al. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 29(4), 650-659 (2008).
25. Wallace DL, Masters JE, De Lara CM et al. Human cytomegalovirus-specific CD8(+) T-cell expansions contain long-lived cells that retain functional capacity in both young and elderly subjects. Immunology 132(1), 27-38 (2011).
26. Hertoghs KM, Moerland PD, van Stijn A et al. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J. Clin. Invest. 120(11), 4077-4090 (2010).
27. Quinn M, Turula H, Tandon M, Deslouches B, Moghbeli T, Snyder CM. Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios. J. Immunol. 194(4), 1726-1736 (2015).
28. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 101(2), 407-414 (2003).
29. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT megafile analysis. Blood 102(13), 4255-4260 (2003).
30. Ringdén O, Schaffer M, Le Blanc K et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A,-B, and-DRB1 genomically identical volunteers. Biol. Blood Marrow Transplant. 10(2), 128-134 (2004).
31. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol. Oncol. Clin. North Am. 25(1), 151-169 (2011).
32. Kurz SK, Rapp M, Steffens HP et al. Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J. Virol. 73(1), 482-494 (1999).
33. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc. Natl Acad. Sci. USA 91(25), 11879-11883 (1994).
34. Hermiston TW, Malone CL, Witte PR, Stinski MF. Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter. J. Virol. 61(10), 3214-3221 (1987).
35. Kurz SK, Reddehase MJ. Patchwork pattern of transcriptional reactivation in the lungs indicates sequential checkpoints in the transition from murine cytomegalovirus latency to recurrence. J. Virol. 73(10), 8612-8622 (1999).
36. Grzimek NK, Dreis D, Schmalz S, Reddehase MJ. Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs. J. Virol. 75(6), 2692-2705 (2001).
37. Henry SC, Hamilton JD. Detection of murine cytomegalovirus immediate early 1 transcripts in the spleens of latently infected mice. J. Infect. Dis. 167(4), 950-954 (1993).
38. Hummel M, Zhang Z, Yan S et al. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: A model for reactivation from latency. J. Virol. 75(10), 4814-4822 (2001).
39. Hunninghake GW, Monick MM, Liu B, Stinski MF. The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J. Virol. 63(7), 3026-3033 (1989).
40. Liu B, Stinski MF. Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. J. Virol. 66(7), 4434-4444 (1992).
41. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J. Virol. 80(18), 9151-9158 (2006).
42. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91(1), 119-126 (1997).
43. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl Acad. Sci. USA 95(7), 3937-3942 (1998).
44. Simon CO, Holtappels R, Tervo HM et al. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J. Virol. 80(21), 10436-10456 (2006).
45. Holtappels R, Bohm V, Podlech J, Reddehase MJ. CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model. Med. Microbiol. Immunol. 197(2), 125-134 (2008).
46. Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99(11), 3916-3922 (2002).
47. Reddehase MJ, Jonjic S, Weiland F, Mutter W, Koszinowski UH. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helperindependent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J. Virol. 62(3), 1061-1065 (1988).
48. Jonjic S, Pavic I, Lucin P, Rukavina D, Koszinowski UH. Efficacious control of cytomegalovirus infection after longterm depletion of CD8+ T lymphocytes. J. Virol. 64(11), 5457-5464 (1990).
49. Casazza JP, Betts MR, Price DA et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp. Med. 203(13), 2865-2877 (2006).
50. van Leeuwen EM, Remmerswaal EB, Vossen MT et al. Emergence of a CD4+CD28-granzyme B+, cytomegalovirusspecific T cell subset after recovery of primary cytomegalovirus infection. J. Immunol. 173(3), 1834-1841 (2004).
51. Gamadia LE, Remmerswaal EB, Weel JF et al. Primary immune responses to human CMV: A critical role for IFNgamma-producing CD4+ T cells in protection against CMV disease. Blood 101(7), 2686-2692 (2003).
52. Jonjic S, Mutter W, Weiland F, Reddehase MJ, Koszinowski UH. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J. Exp. Med. 169(4), 1199-1212 (1989).
53. Walton SM, Mandaric S, Torti N, Zimmermann A, Hengel H, Oxenius A. Absence of cross-presenting cells in the salivary gland and viral immune evasion confine cytomegalovirus immune control to effector CD4 T cells. PLoS Pathog. 7(8), e1002214 (2011).
54. Lucin P, Pavic I, Polic B, Jonjic S, Koszinowski UH. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 66(4), 1977-1984 (1992).
55. Bohm V, Simon CO, Podlech J et al. The immune evasion paradox: Immunoevasins of murine cytomegalovirus enhance priming of CD8 T cells by preventing negative feedback regulation. J. Virol. 82(23), 11637-11650 (2008).
56. Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202(5), 673-685 (2005).
57. Redeker A, Welten SP, Arens R. Viral inoculum dose impacts memory T-cell inflation. Eur. J. Immunol. 44(4), 1046-1057 (2014).
58. Gamadia LE, van Leeuwen EM, Remmerswaal EB et al. The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. J. Immunol. 172(10), 6107-6114 (2004).
59. van Leeuwen EM, de Bree GJ, Remmerswaal EB et al. IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells. Blood 106(6), 2091-2098 (2005).
60. Snyder CM, Cho KS, Bonnett EL, Allan JE, Hill AB. Sustained CD8+ T cell memory inflation after infection with a single-cycle cytomegalovirus. PLoS Pathog. 7(10), e1002295 (2011).
61. Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: A prospective multicenter study. Blood 116(10), 1655-1662 (2010).
62. Nicholson E, Peggs KS. Cytomegalovirus-specific T-cell therapies: current status and future prospects. Immunotherapy 7(2), 135-146 (2015).
63. Smith CJ, Turula H, Snyder CM. Systemic hematogenous maintenance of memory inflation by MCMV infection. PLoS Pathog. 10(7), e1004233 (2014).
64. Torti N, Walton SM, Brocker T, Rulicke T, Oxenius A. Nonhematopoietic cells in lymph nodes drive memory CD8 T cell inflation during murine cytomegalovirus infection. PLoS Pathog. 7(10), e1002313 (2011).
65. Seckert CK, Schader SI, Ebert S et al. Antigen-presenting cells of haematopoietic origin prime cytomegalovirus-specific CD8 T-cells but are not sufficient for driving memory inflation during viral latency. J. Gen. Virol. 92(Pt 9), 1994-2005 (2011).
66. O'Hara GA, Welten SP, Klenerman P, Arens R. Memory T cell inflation: understanding cause and effect. Trends Immunol. 33(2), 84-90 (2012).
67. Iancu EM, Corthesy P, Baumgaertner P et al. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J. Immunol. 183(1), 319-331 (2009).
68. Scheinberg P, Melenhorst JJ, Brenchley JM et al. The transfer of adaptive immunity to cytomegalovirus (CMV) during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 114(24), 5071-5080 (2009).
69. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
70. Cobbs CS, Harkins L, Samanta M et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62(12), 3347-3350 (2002).
71. Harkins L, Volk AL, Samanta M et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360(9345), 1557-1563 (2002).
72. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J. Urol. 170(3), 998-1002 (2003).
73. Harkins LE, Matlaf LA, Soroceanu L et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 1(1), 8 (2010).
74. Price RL, Bingmer K, Harkins L et al. Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/-mice. Cancer Res. 72(22), 5669-5674 (2012).
75. Dey M, Ahmed AU, Lesniak MS. Cytomegalovirus and glioma: Putting the cart before the horse. J. Neurol. Neurosurg. Psychiatry 86(2), 191-199 (2015).
76. Schuessler A, Smith C, Beagley L et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74(13), 3466-3476 (2014).
77. Schuessler A, Walker DG, Khanna R. Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front. Oncol. 4, 275 (2014).
78. Stragliotto G, Rahbar A, Solberg NW et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study. Int. J. Cancer 133(5), 1204-1213 (2013).
79. Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N. Engl. J. Med. 369(10), 985-986 (2013).
80. Söderberg-Nauclér C, Peredo I, Stragliotto G. Valganciclovir in patients with glioblastoma. N. Engl. J. Med. 369(21), 2066-2067 (2013).
81. Nair SK, Sampson JH, Mitchell DA. Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology 3, e29289 (2014).
82. Nair SK, De Leon G, Boczkowski D et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin. Cancer Res. 20(10), 2684-2694 (2014).
83. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol. Cell. Biol. 90(9), 872-880 (2012).
84. Wherry EJ. T cell exhaustion. Nat. Immunol. 12(6), 492-499 (2011).
85. Smith CJ, Caldeira-Dantas S, Turula H, Snyder CM. Murine CMV infection induces the continuous production of mucosal resident T cells. Cell Rep. 13(6), 1137-1148 (2015).
86. Karrer U, Wagner M, Sierro S et al. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J. Virol. 78(5), 2255-2264 (2004).
87. Dekhtiarenko I, Jarvis MA, Ruzsics Z, Cicin-Sain L. The context of gene expression defines the immunodominance hierarchy of cytomegalovirus antigens. J. Immunol. 190(7), 3399-3409 (2013).
88. Hansen SG, Powers CJ, Richards R et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328(5974), 102-106 (2010).
89. Lloyd ML, Shellam GR, Papadimitriou JM, Lawson MA. Immunocontraception is induced in BALB/c mice inoculated with murine cytomegalovirus expressing mouse zona pellucida 3. Biol. Reprod. 68(6), 2024-2032 (2003).
90. Lloyd ML, Papadimitriou JM, O'Leary S, Robertson SA, Shellam GR. Immunoglobulin to zona pellucida 3 mediates ovarian damage and infertility after contraceptive vaccination in mice. J. Autoimmun. 35(1), 77-85 (2010).
91. Klyushnenkova EN, Kouiavskaia DV, Parkins CJ et al. A cytomegalovirus-based vaccine expressing a single tumorspecific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J. Immunother. 35(5), 390-399 (2012).
92. Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. Biochem. Biophys. Res. Commun. 437(2), 287-291 (2013).
93. Qiu Z, Huang H, Grenier JM et al. Cytomegalovirus based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T cell response and protects mice from melanoma. Cancer Immunol. Res. 3(5), 536-546 (2015).
94. Erlach KC, Bohm V, Knabe M, Deegen P, Reddehase MJ, Podlech J. Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med. Microbiol. Immunol. 197(2), 167-178 (2008).
95. Couzi L, Pitard V, Moreau JF, Merville P, Déchanet-Merville J. Direct and indirect effects of cytomegalovirus-induced T cells after kidney transplantation. Front. Immunol. 6, 3 (2015).
96. Green ML, Leisenring WM, Xie H et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122(7), 1316-1324 (2013).
97. Elmaagacli AH, Steckel NK, Koldehoff M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118(5), 1402-1412 (2011).
98. Mohr CA, Arapovic J, Muhlbach H et al. A spread deficient cytomegalovirus for assessment of first target cells in vaccination. J. Virol. 84(15), 7730-7742 (2010).